EU C 001

Drug Profile

EU C 001

Alternative Names: EU-C-001

Latest Information Update: 06 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Developer PresSura Neuro
  • Class Antidepressants; Antiemetics; Anxiolytics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Craniocerebral trauma
  • Preclinical Brain injuries

Most Recent Events

  • 06 Apr 2017 EU C 001 is still in preclinical development for Brain injuries in Australia (PresSura Neuro website, April 2017)
  • 06 Apr 2017 Pharmacodynamics data from preclinical trials in Brain injuries released by PresSura Neuro (PresSura Neuro website, April 2017)
  • 02 Nov 2016 Phase-I clinical trials in Craniocerebral-trauma (In volunteers) in Australia (IV) (ACTRN12616001437459)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top